Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus
- PMID: 33455998
- PMCID: PMC7905302
- DOI: 10.2176/nmc.st.2020-0292
Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus (Third Edition): Endorsed by the Japanese Society of Normal Pressure Hydrocephalus
Abstract
Among the various disorders that manifest with gait disturbance, cognitive impairment, and urinary incontinence in the elderly population, idiopathic normal pressure hydrocephalus (iNPH) is becoming of great importance. The first edition of these guidelines for management of iNPH was published in 2004, and the second edition in 2012, to provide a series of timely, evidence-based recommendations related to iNPH. Since the last edition, clinical awareness of iNPH has risen dramatically, and clinical and basic research efforts on iNPH have increased significantly. This third edition of the guidelines was made to share these ideas with the international community and to promote international research on iNPH. The revision of the guidelines was undertaken by a multidisciplinary expert working group of the Japanese Society of Normal Pressure Hydrocephalus in conjunction with the Japanese Ministry of Health, Labour and Welfare research project. This revision proposes a new classification for NPH. The category of iNPH is clearly distinguished from NPH with congenital/developmental and acquired etiologies. Additionally, the essential role of disproportionately enlarged subarachnoid-space hydrocephalus (DESH) in the imaging diagnosis and decision for further management of iNPH is discussed in this edition. We created an algorithm for diagnosis and decision for shunt management. Diagnosis by biomarkers that distinguish prognosis has been also initiated. Therefore, diagnosis and treatment of iNPH have entered a new phase. We hope that this third edition of the guidelines will help patients, their families, and healthcare professionals involved in treating iNPH.
Keywords: clinical guideline; diagnosis; idiopathic normal pressure hydrocephalus; management; treatment.
Conflict of interest statement
The committee paid for expenses such as meeting venues and transportation for attending the committee meetings. The committee did not pay an honorarium to the committee members or study collaborators for writing manuscripts or participating in meetings.
The present guidelines have been prepared based on appropriate conflict of interest (COI) management by the operating rules of the Japan Neurosurgical Society, the Japanese Society of Neurology, the Japanese Society of Psychiatry and Neurology, and the Japan Radiological Society. The committee members, study collaborators, and evaluation/ coordinating committee members involved in these guidelines submitted self-reports to their respective academic societies regarding their COIs for the past 3 years based on the standards set by the academic societies to which they belong.
Honorarium for executives, stocks, patent royalties, lecture fees, manuscript fees, research expenses, subsidies, travel expenses, gifts, scholarships (encouragements) endowment, affiliation with an endowed chair.
Moreover, all organizations such as corporations targeted for the declaration are all "corporations/corporate organizations related to medical research and organizations for profit-making purposes.” After being reviewed by the COI Review Committee, the Guidelines were prepared/revised according to the results of the review.
The companies declared in the COI are shown below:
Actelion Pharmaceuticals Japan Ltd., Idorsia Pharmaceuticals Japan Ltd., Eisai Co., Ltd., Kaneka Medix Corporation, Software Service, Inc., Terumo Corporation, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Stryker Japan, Nippontectsystems co., Ltd., Nihon Medi-Physics Co., Ltd., Medtronic Japan Co., Ltd., Hitachi, Ltd., Fujitsu Limited, FUJIFILM Corporation, Heptares Therapeutics Ltd., Integra Japan, Mentis Cura Japan, PMOD Inc.
Figures





Similar articles
-
Guidelines for management of idiopathic normal pressure hydrocephalus: second edition.Neurol Med Chir (Tokyo). 2012;52(11):775-809. doi: 10.2176/nmc.52.775. Neurol Med Chir (Tokyo). 2012. PMID: 23183074
-
Guidelines for management of idiopathic normal pressure hydrocephalus.Neurol Med Chir (Tokyo). 2008;48 Suppl:S1-23. doi: 10.2176/nmc.48.s1. Neurol Med Chir (Tokyo). 2008. PMID: 18408356
-
Disproportionately Enlarged Subarachnoid Space Hydrocephalus in Idiopathic Normal-Pressure Hydrocephalus and Its Implication in Pathogenesis.Acta Neurochir Suppl. 2016;122:287-90. doi: 10.1007/978-3-319-22533-3_57. Acta Neurochir Suppl. 2016. PMID: 27165923
-
Diagnostic importance of disproportionately enlarged subarachnoid space hydrocephalus and Callosal Angle measurements in the context of normal pressure hydrocephalus: A useful tool for clinicians.J Neurol Sci. 2024 Nov 15;466:123250. doi: 10.1016/j.jns.2024.123250. Epub 2024 Sep 19. J Neurol Sci. 2024. PMID: 39332282 Review.
-
[Idiopathic normal pressure hydrocephalus--overviews and pathogenesis].Brain Nerve. 2008 Mar;60(3):211-7. Brain Nerve. 2008. PMID: 18402067 Review. Japanese.
Cited by
-
The contribution of cognitive reserve in explaining the dual-task walking performance in iNPH patients: comparison with other cognitive, functional, and socio-demographic variables.Aging Clin Exp Res. 2024 Sep 11;36(1):190. doi: 10.1007/s40520-024-02829-0. Aging Clin Exp Res. 2024. PMID: 39259457 Free PMC article.
-
In Vivo Prevalence of Beta-Amyloid Pathology and Alzheimer's Disease Co-Pathology in Idiopathic Normal-Pressure Hydrocephalus-Association with Neuropsychological Features.Biomedicines. 2024 Aug 20;12(8):1898. doi: 10.3390/biomedicines12081898. Biomedicines. 2024. PMID: 39200362 Free PMC article.
-
Useful outcome measures in INPH patients evaluation.Front Neurol. 2023 Aug 7;14:1201932. doi: 10.3389/fneur.2023.1201932. eCollection 2023. Front Neurol. 2023. PMID: 37609661 Free PMC article.
-
Lipocalin-type prostaglandin D synthase: a glymphopathy marker in idiopathic hydrocephalus.Front Aging Neurosci. 2024 Apr 4;16:1364325. doi: 10.3389/fnagi.2024.1364325. eCollection 2024. Front Aging Neurosci. 2024. PMID: 38638193 Free PMC article.
-
Radiological biomarkers of idiopathic normal pressure hydrocephalus: new approaches for detecting concomitant Alzheimer's disease and predicting prognosis.Psychoradiology. 2022 Nov 28;2(4):156-170. doi: 10.1093/psyrad/kkac019. eCollection 2022 Dec. Psychoradiology. 2022. PMID: 38665278 Free PMC article. Review.
References
-
- Hakim S, Adams RD: The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci 2: 307–327, 1965 - PubMed
-
- Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH: Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure. A treatable syndrome. N Engl J Med 273: 117–126, 1965 - PubMed
-
- Ishikawa M: Guideline Committe for Idiopathic Normal Pressure Hydrocephalus, Japanese Society of Normal Pressure Hydrocephalus: Clinical guidelines for idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 44: 222–223, 2004 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical